Bora expands into the U.S. with Upsher-Smith buy

18 Jan 2024
www.pharmamanufacturing.com
Acquisition
Bora Pharmaceuticals will acquire Upsher-Smith Laboratories, marking the Taiwan-based CDMO's official expansion into the U.S.
Per the deal, Bora will buy Upsher-Smith, a generics manufacturer based in Minnesota, from shareholders Sawai Group Holdings and Sumitomo Corporation of Americas for a total consideration of up to $210 million.
With the acquisition, Bora will get Upsher-Smith's portfolio of 48 generic products as well as two manufacturing facilities in Plymouth and Maple Grove, Minnesota. Combined, the two manufacturing facilities in Minnesota are capable of commercializing a broad range of dosage forms including oral solid, powders (both oral and topical), and liquid, as well as packaging.
Bora, Taiwan’s largest pharmaceutical group by volume, already operates six state-of-the-art CGMP manufacturing facilities, including one in Canada. With its origins as a family-run company, Bora's growth strategy has relied heavily on acquisitions — Upsher-Smith is the seventh in the past nine years and represents a pivotal expansion of Bora’s presence in the U.S. market.
“Bora’s goal has always been to become a world-leading CDMO. To do so, we need to have strategically located development and manufacturing sites all over the world,” said Bora CEO Bobby Sheng in a previous interview with Pharma Manufacturing.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.